Alnylam Pharmaceuticals, Inc.
ALNYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Alnylam Pharmaceuticals, Inc. focuses on Biotechnology services and products. Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. Valued at $29.98B, ALNY is a large-cap name in its sector. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Market Cap
$29.98B
Beta
0.27
P/E (TTM)
37.78
P/E (Fwd)
18.14
EPS (TTM)
$5.93
EPS (Fwd)
$12.35
ROE
96.6%
ROA
12.3%
Cash
$3.31B
Total Debt
$2.99B
Free CF
$271.5M
52W Change
-53.2%
Annual Financials
Cash vs Debt
Where ALNY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALNY finished 15.54% below its 150-day moving average ($276.21) and 20.51% below its 200-day moving average ($293.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALNY overbought or oversold?
At the October 20, 2026 close, ALNY's RSI(14) was 35.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.31B in cash and $2.99B in debt, ALNY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $271.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 96.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.3% further supports the picture of efficient asset utilization. Revenue has grown from $1.04B (2022) to $3.71B (2025), reflecting a 258% increase over the period.
The relatively low beta of 0.27 suggests ALNY is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALNY.